The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

BACKGROUND: The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on management of patients with HER2+ breast cancer, leading to development and increased use of further HER2 targeted therapies. The major clinical side effect is cardiotoxicity but the mechanism is largely unknown. On...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Transl Med
Main Authors: Necela, Brian M., Axenfeld, Bianca C., Serie, Daniel J., Kachergus, Jennifer M., Perez, Edith A., Thompson, E. Aubrey, Norton, Nadine
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2017
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5243239/
https://ncbi.nlm.nih.gov/pubmed/28101782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-016-0133-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki